High clusterin expression correlates with a poor outcome in stage II colorectal cancers

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 2, 2009, Pages 393-399

  Kevans, David ^a   Foley, Jane ^a   Tenniswood, Martin ^b   Sheahan, Kieran ^a   Hyland, John ^a   O'Donoghue, Diarmuid ^a   Mulcahy, Hugh ^a   O'Sullivan, Jacintha ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLUSTERIN; DEOXYURIDINE TRIPHOSPHATE PYROPHOSPHATASE; DNA NUCLEOTIDYLEXOTRANSFERASE;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; CYTOPLASM; FEMALE; HUMAN; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; CLUSTERIN; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU NICK-END LABELING; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; REPRODUCIBILITY OF RESULTS; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL;

EID: 60549086588     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0302     Document Type: Article

References (42)

1. Trougakos IP, Gonos ES. Clusterin/apolipoprotein J in human aging and cancer. Int J Biochem Cell Biol 2002;34:1430-48.
2. Pucci S, Bonanno E, Pichiorri F, Angeloni C, Spagnoli LG. Modulation of different clusterin isoforms in human colon tumorigenesis. Oncogene 2004;23:2298-304.
3. Shannan B, Seifert M, Leskov K, et al. Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer. Cell Death Differ 2006;13:12-9.
4. Andersen CL, Schepeler T, Thorsen K, et al. Clusterin expression in normal mucosa and colorectal cancer. Mol Cell Proteomics 2007;6: 1039-48.
5. Wilson MR, Easterbrook-Smith SB. Clusterin binds by a multivalent mechanism to the Fc and Fab regions of IgG. Biochim Biophys Acta 1992;1159:319-26.
6. de Silva HV, Harmony JA, Stuart WD, Gil CM, Robbins J. Apolipoprotein J: structure and tissue distribution. Biochemistry 1990;29:5380-9.
7. Jenne DE, Lowin B, Peitsch MC, Bottcher A, Schmitz G, Tschopp J. Clusterin (complement lysis inhibitor) forms a high density lipoprotein complex with apolipoprotein A-I in human plasma. J Biol Chem 1991;266:11030-6.
8. Matsubara E, Soto C, Governale S, Frangione B, Ghiso J. Apolipoprotein J and Alzheimer's amyloid β solubility. Biochem J 1996;316: 671-9.
9. Li DQ, Ljungh A. Binding of human clusterin by Staphylococcus epidermidis. FEMS Immunol Med Microbiol 2001;31:197-202.
10. Kujiraoka T, Hattori H, Miwa Y, et al. Serum apolipoprotein j in health, coronary heart disease and type 2 diabetes mellitus. J Atheroscler Thromb 2006;13:314-22.
11. Bajari TM, Strasser V, Nimpf J, Schneider WJ. A model for modulation of leptin activity by association with clusterin. FASEB J 2003;17:1505-7.
12. Matsuda A, Itoh Y, Koshikawa N, Akizawa T, Yana I, Seiki M. Clusterin, an abundant serum factor, is a possible negative regulator of MT6-MMP/MMP-25 produced by neutrophils. J Biol Chem 2003; 278:36350-7.
13. Poon S, Treweek TM, Wilson MR, Easterbrook-Smith SB, Carver JA. Clusterin is an extracellular chaperone that specifically interacts with slowly aggregating proteins on their off-folding pathway. FEBS Lett 2002;513:259-66.
14. Leskov KS, Klokov DY, Li J, Kinsella TJ, Boothman DA. Synthesis and functional analyses of nuclear clusterin, a cell death protein. J Biol Chem 2003;278:11590-600.
15. Miyake H, Nelson C, Rennie PS, Gleave ME. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. Cancer Res 2000;60:2547-54.
16. Cervellera M, Raschella G, Santilli G, et al. Direct transactivation of the anti-apoptotic gene apolipoprotein J (clusterin) by B-MYB. J Biol Chem 2000;275:21055-60.
17. Miyake H, Yamanaka K, Muramaki M, Kurahashi T, Gleave M, Hara I. Enhanced expression of the secreted form of clusterin following neoadjuvant hormonal therapy as a prognostic predictor in patients undergoing radical prostatectomy for prostate cancer. Oncol Rep 2005;14:1371-5.
18. Kurahashi T, Muramaki M, Yamanaka K, Hara I, Miyake H. Expression of the secreted form of clusterin protein in renal cell carcinoma as a predictor of disease extension. BJU Int 2005;96:895-9.
19. XieD,Lau SH,ShamJS, et al.Up-regulatedexpression of cytoplasmic clusterin in human ovarian carcinoma. Cancer 2005; 103:277-83.
20. Watari H, Ohta Y, Hassan MK, Xiong Y, Tanaka S, Sakuragi N. Clusterin expression predicts survival of invasive cervical cancer patients treated with radical hysterectomy and systematic lympha-denectomy. Gynecol Oncol 2008;108:527-32.
21. Kang YK, Hong SW, Lee H, Kim WH. Overexpression of clusterin in human hepatocellular carcinoma. Hum Pathol 2004;35:1340-6.
22. Xie MJ, Motoo Y, Su SB, et al. Expression of clusterin in human pancreatic cancer. Pancreas 2002;25:234-8.
23. Albert JM, Gonzalez A, Massion PP, et al. Cytoplasmic clusterin expression is associated with longer survival in patients with resected non small cell lung cancer. Cancer Epidemiol Biomarkers Prev 2007;16:1845-51.
24. Redondo M, Villar E, Torres-Munoz J, Tellez T, Morell M, Petito CK. Overexpression of clusterin in human breast carcinoma. Am J Pathol 2000;157:393-9.
25. Chen X, Halberg RB, Ehrhardt WM, Torrealba J, Dove WF. Clusterin as a biomarker in murine and human intestinal neoplasia. Proc Natl Acad Sci U S A 2003;100:9530-5.
26. Lakins J, Bennett SA, Chen JH, et al. Clusterin biogenesis is altered during apoptosis in the regressing rat ventral prostate. J Biol Chem 1998;273:27887-95.
27. Petersen VC, Baxter KJ, Love SB, Shepherd NA. Identification of objective pathological prognostic determinants and models of prognosis in Dukes' B colon cancer. Gut 2002;51:65-9.
28. Andre T, Sargent D, Tabernero J, et al. Current issues in adjuvant treatment of stage II colon cancer. Ann Surg Oncol 2006;13:887-98.
29. Jenne DE, Tschopp J. Clusterin: the intriguing guises of a widely expressed glycoprotein. Trends Biochem Sci 1992;17:154-9.
30. Appel D, Pilarsky C, Graichen R, Koch-Brandt C. Sorting of gp80 (GPIII, clusterin), a marker protein for constitutive apical secretion in Madin-Darby canine kidney (MDCK) cells, into the regulated pathway in the pheochromocytoma cell line PC12. Eur J Cell Biol 1996;70:142-9.
31. Sensibar JA, Sutkowski DM, Raffo A, et al. Prevention of cell death induced by tumor necrosis factor α in LNCaP cells by over-expression of sulfated glycoprotein-2 (clusterin). Cancer Res 1995; 55:2431 -7.
32. Bursch W, Gleeson T, Kleine L, Tenniswood M. Expression of clusterin (testosterone-repressed prostate message-2) mRNA during growth and regeneration of rat liver. Arch Toxicol 1995;69: 253-8.
33. Helvering LM, Richardson KK, Horn DM, et al. Expression of TRPM-2 during involution and regeneration of the rat liver. Cancer Lett 1993;71:133-42.
34. Marinelli M, Quaglino D, Bettuzzi S, Strocchi P, Davalli P, Corti A. Increased levels of clusterin mRNA in the ventral prostate of the aging rat are associated to increases in cuboidal (atrophic) cell population and not to changes in apoptotic activity. Biochem Cell Biol 1994;72:515-21.
35. Sensibar JA, Liu XX, Patai B, Alger B, Lee C. Characterization of castration-induced cell death in the rat prostate by immunohisto-chemical localization of cathepsin D. Prostate 1990;16:263-76.
36. Zhang H, Kim JK, Edwards CA, Xu Z, Taichman R, Wang CY. Clusterin inhibits apoptosis by interacting with activated Bax. Nat Cell Biol 2005;7:909-15.
37. Criswell T, Klokov D, Beman M, Lavik JP, Boothman DA. Repression of IR-inducible clusterin expression by the p53 tumor suppressor protein. Cancer Biol Ther 2003;2:372-80.
38. Santilli G, Aronow BJ, Sala A. Essential requirement of apolipoprotein J (clusterin) signaling for IκB expression and regulation of nF-kappa;B activity. J Biol Chem 2003;278:38214-9.
39. Gleave M, Jansen B. Clusterin and IGFBPs as antisense targets in prostate cancer. Ann NY Acad Sci 2003;1002:95-104.
40. Criswell T, Beman M, Araki S, et al. Delayed activation of insulin-like growth factor-1 receptor/Src/MAPK/Egr-1 signaling regulates clusterin expression, a pro-survival factor. J Biol Chem 2005;280: 14212-21.
41. Gleave M, Miyake H. Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemosensitivity in prostate cancer. World J Urol 2005;23:38-46.
42. Miyake H, Hara I, Gleave ME. Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic. Int J Urol 2005;12:785-94.